Schema-Root.org logo

 

  cross-referenced news and research resources about

 PhaRMA

Representing 50 biotech companies, PhRMA has twenty registered lobbyists on staff and has contracted with dozens of lobby and public relations firms — including Akin, Gump, Strauss, Hauer & Feld, Barbour Griffith & Rogers, DCI Group, The Dutko Group, Edelman, and Bonner & Associates — to promote its members' interests. Total lobbying expenditures in 2009 were $26,465,520

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Mon. March 26, 2018

-
(KUTV) - Summit County filed a lawsuit against opioid drug manufacturers and opioid distributors Tuesday in Utah's Third Judicial District Court for Summit County. The lawsuit alleges the current nationwide opioid crisis was created "by misinformation, false claims, and marketing by the manufacturers and distributors of ...
The role will position him on the other side of the negotiating table from his former employer and plenty of other pharma companies as a battle over drug pricing wages on. He's the second top Big pharma ex to move into the payer world this month, following former GlaxoSmithKline CEO Andrew Witty, ...

"I almost got fired for defacing the corporate uniform ... Conformity was "not my strong suit." -- Lisa Bair. Long before she founded and led companies, Lisa Bair sold fried chicken in brown polyester bell-bottom pants one summer after high school. She took the initiative to sew her way into an ...
Johnson & Johnson CFO Dominic Caruso is planning to retire in September. "Dominic made a big impact inside our company, and he is well-respected throughout our industry," said CEO Alex Gorsky. He will be replaced by Joseph Wolk, VP of investor relations, who has worked at J&J for 19 years.
Biotech company Amgen has selected Omnicom Media Group agency Hearts & Science as its media agency of record, following a review launched in October and handled by Ark Advisors, Omnicom Media Group confirmed. Omnicom sister shop SSCG retained media duties for Amgen brands marketed ...

As pharma products launch into increasingly competitive markets, branding becomes more important. And that's why FCB Health has launched BX: Brand Experience Design Group, its first stand-alone, full service branding agency focused on health and wellness. The newly independent agency will ...
GlaxoSmithKline commences late stage study with Benlysta (belimumab) and Roche's Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). Analysis focus: Arena Pharmaceuticals. Today we will discuss Arena Pharmaceuticals (NASDAQ:ARNA), which was up nearly 30% ...
Miels - a long-time protege of AstraZeneca CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis and Merck in producing ...
The FDA is taking steps towards limiting the amount of nicotine allowed in cigarettes. The government agency said in an advanced notice that it is working towards a guideline “where nicotine levels in cigarettes do not spur or sustain addiction for some portion of potential smokers.” (CNBC).
The law firm of Baron & Budd will serve as a lead firm in a new lawsuit on behalf of Milwaukee County against many of the nation's largest pharmaceutical manufacturers and distributors for their role in creating a widespread diversion of prescription opiates for nonmedical purposes. The case was filed in ...
RALEIGH – More than 1,000 pharmaceutical manufacturing leaders gathered at the Raleigh Convention Center Tuesday focused on cutting-edge technologies designed to improve the delivery of drugs to patients with life-threatening illnesses. The 25th Annual Life Sciences and Technology Conference, ...
The biopharma industry faced plenty of uncertainty in 2017, but for most companies, the year delivered a rebound from stagnation, EP Vantage reports. Some rebounded far more than others—and some went the other direction. And there was one clear and overwhelming winner: AbbVie, which more than ...
"There is a growing body of research showing that the 340B program is driving up costs for patients and the health care system," said Stephen J. Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA). "The biopharmaceutical industry has long supported the 340B ...
Analysts who follow the field say digital products are getting more direct attention from pharma CEOs who now see their development as a business imperative, as opposed to a supplemental service with marginal importance to their companies. “The CEOs are coming to us and saying, 'I have a strategic ...
China's enormous population, coupled with the rise of disease and illness, make the country a prime market for pharmaceutical companies, one in which U.S. and British pharma heavyweights are increasingly investing. Xi plans to improve the Chinese pharmaceutical industry to counter this reliance on ...

Matt Bevin seeking to recover legal fees from a law firm over a settlement with drug manufacturer Purdue Pharma over marketing of the addictive narcotic drug OxyContin. Franklin Circuit Judge Thomas Wingate on Monday dismissed efforts by Bevin's Finance Secretary, William Landrum, to recover $4.2 ...
Five things for pharma marketers to know: Tuesday, February 27, 2018. Share this content: Email; Print. Apple is planning to roll out ... Pharma companies are set to begin lobbying for antibiotic incentives in a new version of a pandemic preparedness bill. The 2013 update of the law, the Pandemic and ...
Today we will discuss Progenics Pharmaceuticals (PGNX), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a significant boost to the stock price. On April 30th, the FDA will ...
With all of the drama surrounding executive leadership and cash burn at Synergy Pharma (SGYP), the market hasn't focused as much on the prescription data of Trulance. The stock has held close to $2 suggesting healthy investor appetite for the biotech at this level, but meeting 2018 targets could create ...
The broad market seems to be on its way to make new highs but a small 2-3% pullback may be due this week. How to interpret Mesoblast's (MESO) phase 3 results in steroid-refractory acute graft versus host disease? How to interpret DBV Technologies' (DBVT) phase 2 cow's milk allergy data? The broad ...
"Pharma bro" fraudster Martin Shkreli's hopes for a light prison sentence were dealt a huge blow Monday as a judge ruled that his crimes caused a loss of $10.4 million. The ruling by Judge Kiyo Matsumoto means that federal sentencing guidelines will likely call for a prison term of up to a decade or more ...
The script also takes a withering look at Big Pharma and the ethics and morality involved in drug testing human guinea pigs. To add to the tangle of interests, the female doctor suffers from deep depression. Prebble structured the play in fragments, with dislocations of time and space. “It's like a Christmas ...
STAMFORD — OxyContin maker Purdue Pharma ranked as the top donor among a group of five pharmaceutical companies that poured millions of dollars during the past five years into prominent nonprofits supporting large-scale opioid use, according to a new report from U.S. Sen. Claire McCaskill.
(RTTNews.com) - The week that rolled by witnessed some big pharma names signing on the dotted line for collaborative research in the fields of Alzheimer's and Cancer. AbbVie Inc. ( ABBV ) and Voyager Therapeutics (VYGR), on Feb.21, 2018, announced that they are teaming up to develop gene ...
Eli Lilly & Co. made the declaration in response to a shareholder resolution that would require the company to support cannabis descheduling. 0. SHARES. ShareTweetRedditWhatsappMailPrint · GoogleTumblrPinterestLinkedinPocketDiggStumbleupon. Published: Feb 23, 2018, 5:17 pm • Updated: about an hour ago.
Today we will discuss Clovis Oncology (CLVS). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45. The gains this week have been driven by Clovis' announcement that it ...
Martin Shkreli, the smirking "pharma bro" who gained worldwide infamy by raising the price of a lifesaving drug 5,000 percent, is awaiting sentencing next month on three counts of securities fraud. But as told on the season premiere of CNBC's "American Greed," Shkreli's crimes have nothing to do with the ...
The pharmaceutical industry is using a large portion of its windfall from Republicans' corporate tax cuts to boost its stock prices. Nine drug companies are spending a combined $50 billion on new share buyback programs, a sum that towers over investments in employees or drug research and development. The bottom line: ...
Cardiome Pharma Corp (TSX:COM), a CA$62.69M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities. The environment facing ...
Today we will discuss AbbVie (ABBV), which continues to have a phenomenal run in 2018 even as sentiment on the broader equity market has turned negative. After posting strong gains in 2017, AbbVie is already up more than 22% for 2018, outperforming both the NBI and the S&P 500. The gains for ...
Bal Pharma Limited (NSEI:BALPHARMA), a IN₨1.34B small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities. Pharma companies, in particular, are ...
It's a depressingly common aphorism in Washington policy-making circles that “pharma always wins.” This happens regardless of the merits of any particular policy — in fact, the more “pharma always wins,” the more often taxpayers and consumers lose. Nevertheless, the industry keeps racking up ...
Harbin Pharmaceutical Group (Hayao) will invest $300 million in GNC Holdings (NYSE: GNC), a US company that makes nutritional supplements. Hayao will also form a JV with GNC to make and distribute GNC supplements in China. After the transaction, Hayao will be GNC's largest shareholder with a ...
If the devil wears Prada, what do America's most destructive drug pushers wear? They wear smiles. The drug pushers we have in mind here have caused hundreds of thousands of deaths, enough fatalities to decrease overall U.S. life expectancy at birth for the last two years running. Yet no police SWAT ...
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)'s kinase switch control platform has largely gone unnoticed on the Street. The nascent portfolio caught an analyst's attention this week. The Rating. B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43 price target.
Goldacre has spent years campaigning to force companies to report in all their clinical trials; many of the drugs on the market today were approved even though more than half of their trials never reported in, meaning that pharma companies were able to cherry-pick the trials that yielded favorable results ...
Manhattan oncology data company Flatiron Health said Thursday it has agreed to be acquired by the Swiss drugmaker Roche for $1.9 billion. The landmark deal signals the growing strength of the city's health technology sector. Flatiron sells a specialized electronic health record system for oncology and ...
Hyderabad, called “bulk drug capital of India”, contributes almost 20 per cent of pharma exports from India and generates US$15 billion a year, according to the federal finance ministry. The city plays a major role in making India a leader in the global generic drug business and clinical research outsourcing.
Pharma unleashes lobbying power to fight surprising—and costly—changes to Medicare Part D ... Pharma only recently suffered in Congress' shutdown-averting spending deal, which put the industry on the hook for bigger discounts in the Medicare Part D coverage gap, but its advocates in Washington are ...
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase Pharma's (TTPH) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaogen's plazomicin NDA is currently being reviewed by the FDA for the ...
Some of the pharmaceutical companies selling prescription opioids that have caused thousands of deaths are looking to profit from the antidote for overdoses, according to a VICE News analysis of drug approval records from Health Canada. One emergency room doctor in Toronto who regularly reverses ...
Astellas Pharma buying Universal Cells for $102M in Seattle's third biotech acquisition in a month. by Clare McGrane on February 15, 2018 at ... Astellas Pharma, a Japanese pharmaceutical and biotechnology company, is acquiring Seattle biotech Universal Cells. Astellas will pay up to $102.5 million for ...
The sticker shock for Horizon Pharma's Vimovo drug is magnified by the fact that the painkiller's two main ingredients can be purchased separately — for just $36. Although patients typically pay just a fraction of the price for Vimovo, the dramatic price increase underlines what critics describe as a murky and ...
Today we will discuss Shire Plc (SHPG), which is continuing with its bad run. Year to date, SHPG shares have fallen nearly 14%. Of course, the sell-off this year can be attributed to the bearish sentiment in general in the market. But Shire also had a disappointing 2017 even as the NBI posted gains of more ...
Antares Pharma stock is also rising on this news because the newly approved device utilizes the company's QuickShot technology. Under the terms of the agreement between these two companies, Antares will assemble the final product and then sell it back to AMAG at cost plus a markup. Antares is then ...
Roche, the global pharmaceutical company from Switzerland, today announced it will scoop up Flatiron Health, a startup analyzing real-time oncology data to help cancer patients and doctors, in a $1.9 billion deal. Flatiron has also confirmed the deal to TechCrunch. Two years ago, Roche led a $175 ...
Shares of Antares Pharma Inc. ATRS, +18.69% and Amag Pharmaceuticals AMAG, +29.14% soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector drug-device combination product, a ready-to-administer ...
A recent article arguing that “brands don't matter to patients” (Accenture Life Sciences, “The Patient Has Spoken”) draws some conclusions that are worthy of debate and challenge. While it's a compelling survey, I confess I struggle to accept as inevitable the conclusion that “product brands are not major ...


 

news and opinion


 


 


 


 


schema-root.org

   lobbyists
     phrma

lobbyists:
     alston & bird
     capitoline
     phrma